News

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

Breakthrough technologies are raising the ceiling for functional visual outcomes

What to expect from 4 days in the Fortezza de Basso

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA).

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients. Topline data is anticipated in 2026.

The Advanced Research Projects Agency for Health award has established a multidisciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation, with the goal of bringing sight to those who are blind through the first-ever successful vision recovery in 6 whole eye transplants in humans by 2030.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The trial is expected to close randomization in early December 2024.

Gauging patient perceptions in an ethnically diverse UK cohort

A team of Bascom Palmer Eye Institute and University of Miami researchers have received an award to fund the procurement, preservation, and transplantation of a human eye to restore vision.

PolyActiva’s phase 2 clinical trial of its PA5108 glaucoma implant met efficacy and safety end points, demonstrating more than 20% reduction in IOP. The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy.

The organization will provide resources for spreading awareness and educating patients and care givers.

The authors analysed severity and frequency of ocular pain among patients with DED living in altitudes above 2,500 meters during the COVID-19 pandemic

Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization offers free educational resources, including videos and guides, and supports GA patients through programs like Living Well With Low Vision.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Welcome to the latest edition of This Week in Ophthalmology, a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Hyaluronic acid fillers are used for undereye volume correction, detailing aging effects on facial anatomy, common complications, and optimal injection techniques. Imaging tools such as MRI can prove to be beneficial for patient assessment.

Preclinical research highlights mRNA-based therapy's potential to inhibit scar tissue and abnormal blood vessel growth in proliferative vitreoretinopathy, addressing a critical unmet need in treatment.

About 33% of ocular tuberculosis patients may relapse within 2 years of achieving clinical inactivity, with a poor initial treatment response serving as a strong predictor of recurrence.

A Korean study identified preoperative use of preservative-containing glaucoma medications as a significant risk factor for trabeculectomy failure in POAG patients. The Glaucoma Medication Intensity Index (GMII) predicted long-term outcomes, highlighting the importance of managing medication exposure before surgery.

With news of several biosimilar candidates moving along the path of approval, Modern Retina is taking a moment to recap the updates on the state of these biosimilars.

A higher body mass index was protective against glaucoma progression, while patients who were underweight had significantly faster rates of structural loss